Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant propranolol monotherapy window study in angiosarcoma
NL-OMON49514Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of propranolol in angiosarcoma and cutaneous angiosarcoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical response. Started Mar 2020; status: completed.
02
Drugs
propranolol
03
Conditions
angiosarcomacutaneous angiosarcoma
Beyond the preview
Go deeper on NL-OMON49514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49514.